Varicella Vaccination Program

Progress and Challenges

Jane Seward, MBBS, MPH Centers for Disease Control and Prevention National Immunization Conference, Chicago, March 18, 2003




Progress

- Vaccine impact on mortality and morbidity
 - Decline in varicella cases
 - Decline in varicella hospitalizations
 - Decline in varicella deaths
- Vaccine
 - Coverage including child care and school requirements
 - Safety
 - Effectiveness



onthly Varicella Cases and Vaccine Coverag Antelope Valley, CA, 1995 – 2002




Reduction (%) of Varicella Cases by Age Varicella Active Surveillance Sites, Jan-Sept 1995 to 2002

Age group	Antelope Valley, CA	West Philadelphia
< 1	91	78
1-4	94	87
5-9	78	91
10-14	71	89
15-19	82	77
20+	79	46
Total	<mark>89</mark>	<mark>87</mark>

CDC Immunization

Varicella Outbreaks and Number of Outbreak-related Cases Antelope Valley, CA, 1995-2002



SAFER • HEALTHIER • PEOPLE[™] DEPARTMENT OF HEALTH AND HUMAN SERVICES 8 cases /outbrea




Reduction in Varicella Cases Reported to National Notifiable Disease Surveillance System USA, 4 States, 1993-1995 and 2002

	Reduction in varicella cases in 2002 compared to average cases 1993-95	Vaccine coverage 2001
Texas	85 %	84%
Michigan	84 %	77%
West Virginia	72 %	82%
Illinois	65%	57%



Varicella Hospitalizations, 1995-2001 3 Active Surveillance Areas





Varicella Deaths among Children and Adolescents < 20 years, U.S., 1990-2000





Varicella Deaths Reported in 2002


- 9 year old healthy, unvaccinated child
 Invasive Group A Streptococcus sepsis
 - Exposed in after-school child care and/or school setting to unvaccinated children
- 37 year old healthy, unvaccinated male
 Pneumonia and other complications
 - Exposure from unvaccinated 9 year old daughter



Vaccine Coverage, Safety and Effectiveness



Varicella Vaccine Coverage, U.S. Children 19-35 Months National Immunization Survey



DEPARTMENT OF HEALTH AND HUMAN SERVICES



State Requirements for Varicella Vaccine for Child Care or School Entry

By January 2003

- 35 states had implemented child care or school requirements
 - 30 states childcare and school
 - 3 states childcare only
 - 2 states school only



Varicella Vaccine Safety*

- Serious adverse events very rare
 - 2.9 reported per 100,000 doses
- Deaths: most have definite or plausible other explanations or insufficient information to determine causality
- Herpes zoster in healthy vaccinees but rate < natural disease
- Secondary transmission from healthy vaccinees extremely rare

Vise RP et al JAMA, 2000. Sharrar R et al Vaccine 2000, Black S et al PIDJ 1999



The New England Journal of Medicine

Copyright © 2002 by the Massachusetts Medical Society

VOLUME 347

December 12, 2002

NUMBER 24



OUTBREAK OF VARICELLA AT A DAY-CARE CENTER DESPITE VACCINATION

KARIN GALIL, M.D., M.P.H., BRENT LEE, M.D., M.P.H., TARA STRINE, M.P.H., CLAIRE CARRAHER, R.N., Andrew L. BAUGHMAN, Ph.D., M.P.H., MELINDA EATON, D.V.M., JOSE MONTERO, M.D., AND JANE SEWARD, M.B., B.S., M.P.H.

VARICELLA VACCINE — ARE TWO Doses Better Than One?

ANNE A. GERSHON, M.D.

Columbia University College of Physicians and Surgeons New York, NY 10032



Varicella Outbreak in Day Care Center New Hampshire, 2001

 Overall vaccine effectiveness = 44.0% (95% CI 6.9 – 66.4)

 Effectiveness for prevention of moderate or severe disease = 86.0% (95% CI 38.7–96.8%)

*Galil K et al. N Engl J Med. 2002;347:1909-15



Post-licensure Varicella Vaccine Effectiveness

Study	Vaccine Effectiveness		Study method
	All disease	Mod/severe dz	Setting/Design
Outbreaks N=15	71%-100%	93-100%	Outbreak investigations
			Child care centers, schools
Galil, NEJM, 2002	44% (-6, 67%)	86%	Child care center
Outbreak MD	59% (-1, 84%)	75%	School
Clements, PIDJ, 1999	83% (67-90%)	100%	CCC prospective cohort
/azquez, NEJM, 2001	85% (78-90%)	97%	Case control, clinical practice
Seward, (Prel. 2003)	79% (70-85%)	93% (84 -97%)	SAR in households, VASP site



Challenges

- Implementing school requirements especially for older children
- Vaccine effectiveness and risk factors for vaccine failure
- Understanding breakthrough disease
- Predictions for an increase in herpes zoster (modeling)




Importance of School Requirements

- Change in varicella epidemiology
- Decline in exposure
- Potential for increasing proportion of susceptible older children, adolescents and adults



Monitoring Varicella Immunity and Immunization Levels, Massachusetts

Varicella history Vaccination



Communicating Ballanced Perspective on Vaccine Effectiveness

- One low vaccine effectiveness estimate
- Many normal effectiveness estimates using a variety of study methods
- Excellent protection against moderate and severe disease
- Dramatic disease decline



Risk Factors for Vaccine Failure

- Age (likelihood of exposure)
- Asthma/Reactive airway disease and/or steroids
- Younger age at vaccination
- Longer time since vaccination
- Varicella and MMR vaccine interval < 28 days





- Findings to date do not indicate a need for policy change
- Study phase IV data, vaccinated cohort of 90,000 children
- Independent effects of risk factors



Breakthrough Disease

- Varicella in person vaccinated > 42 days before rash onset
- Milder than natural disease
- Does not appear to increase with time since vaccination
- Transmission occurs in family and outbreak settings
- Continue to study clinical and public health significance



Concerns with Childhood Varicella Vaccination Program

Exposure to VZV virus may boost immune response, preventing or postponing development of zoster

Hope-Simpson, 1965




Varicella and Herpes Zoster

- Does exposure to varicella help maintain immunity and modify risk of herpes zoster?
- Immunity to herpes viruses complex
 - Role of internal boosting?
 - Role of external boosting?
 - Duration of protection from boosts?
- Inactivated varicella vaccine decreased risk of herpes zoster in bone marrow transplant patients
- Adult vaccine trial for prevention/modification of H. zoster



Predicted Impact of Varicella Vaccination on Herpes Zoster



Herpes Zoster Surveillance in the United States



Varicella and Herpes Zoster Disease Trends

Varicella active surveillance sites

- Philadelphia: zoster cases reportable since 1995
- 2 sites: investigations of zoster cases < 20 years

Massachusetts


 State-wide surveillance using survey methods since 1998 (BRFSS)

Seattle – Health Maintenance Organization

 Medical encounter and telephone consultation records since 1992



Age Adjusted Varicella Incidence Froup Health Cooperative, Seattle, 1992-200




* Age adjusted to 1995 GHC population

SAFER • HEALTHIER • PEOPLE[™] Department of Health and Human Services




*Age Adjusted H. Zoster Incidence GHC, Seattle, 1992-2001



* Age adjusted to 1995 GHC population



Incidence Rate of H. Zoster by Age and Year, GHC, Seattle, 1992-2001



SAFER • HEALTHIER • PEOPLE[™] DEPARTMENT OF HEALTH AND HUMAN SERVICES **CDC** Immunization

Summary

- Varicella vaccine is safe and effective
- Decline in varicella cases, hospitalizations and deaths
- Reduced disease transmission
- Importance of school requirements
- Importance of national monitoring for herpes zoster as well as varicella





- State, City and County Health Departments
- Project staff varicella active surveillance project
 - LA County: T. Maupin, L. Mascola, R. Civen
 - Philadelphia: B. Watson,
 D. Perelli, C. Heath
 - Travis County, TX: L. Tabony, J. Pelosi
- John Edmunds (UK)
- GHC, Seattle: L. Jackson, K. Bohkle
- Mass. BRFSS: S. Lett, K. Yih, D. Brooks

- CDC
 - NIP/ESD/VVPDB: Varicella staff, EISO and fellows
 - A. Jumaan, P. Garguillo, R. Harpaz. L. Zimmerman, J. Zhang, M. Marin & H. Nguyen
 - Staff who assisted with outbreaks
 - NIP/ESD/VSB: Vaccine safety staff, EISO
 - NIP/DMD: NIS
 - NCID: National VZV lab
 - S. Schmid, V. Loparev
 - NCHS: mortality data
- FDA: R. Wise, P. Krause, others (vaccine safety)

